All sponsors

Astellas Pharma Global Development, Inc. $4503.T

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS22
PHASE 3 / 2-310
RECRUITING11
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO62%

Delay Index: of 13 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +18.0 months). See all sponsors →

Open Astellas Pharma Global Development, Inc. on the live radar map → 📅 $4503.T readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Spotlight
NCT03504397
P3Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer5652022-09-09 (+19 mo)
GLOW
NCT03653507
P3Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer5072022-10-25 (+15 mo)
EV-302
NCT04223856
P3Active, not recruitingUrothelial Cancer8862023-08-08 (-3 mo)
enfortumab vedotin
NCT04225117
P2Active, not recruitingLocally Advanced or Metastatic Malignant Solid Tumors3292025-02-25 (+23 mo)
Fezolinetant
NCT06440967
P3Active, not recruitingHot Flashes9822026-06-25 (-4 mo)
zolbetuximab
NCT03816163
P2Active, not recruitingPancreatic Cancer; Metastatic Pancreatic Cancer3932026-10-31 (+57 mo)
XNW27011
NCT06792435
P1/2Active, not recruitingPancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC)2402026-12-30 (+18 mo)
ILUSTRO
NCT03505320
P2Active, not recruitingPharmacokinetics of Zolbetuximab; Gastric Cancer1432027-06-30 (+87 mo)
Roxadustat
NCT05970172
P3Active, not recruitingChronic Kidney Disease; Renal Anemia982027-10-30 (+23 mo)
Enfortumab Vedotin
NCT07475806
P2RecruitingMuscle-invasive Bladder Cancer2402027-11-30
Gilteritinib
NCT05520567
P1/2Active, not recruitingAcute Myeloid Leukemia (AML); FLT3-mutated Acute Myeloid Leukemia702028-07-31 (+5 mo)
LUCERNA
NCT06901531
P3RecruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer5002028-09-30 (-15 mo)
ASP2998
NCT07287995
P1/2RecruitingLocally Advanced or Metastatic Malignant Solid Tumors4282029-06-30
enzalutamide
NCT02960022
P2Active, not recruitingProstate Cancer9002029-07-31 (+98 mo)
ASP546C
NCT07488676
P1/2RecruitingGastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma1502029-07-31
Setidegrasib
NCT07409272
P3RecruitingPancreatic Cancer; Metastatic Pancreatic Cancer6142029-08-31
ASP388B
NCT07730021
P1/2RecruitingLocally Advanced or Metastatic Solid Tumors3922030-02-28
Enfortumab vedotin
NCT07566156
P3RecruitingUrothelial Cancer; Urinary Bladder Neoplasms3902030-03-31
Setidegrasib
NCT07566052
P3RecruitingNon-small Cell Lung Cancer (NSCLC)3562030-06-30
ASP2767
NCT07770685
P1/2RecruitingGlaucoma1562030-07-31
ASP2138
NCT07673887
P3RecruitingGastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma5702031-02-28
ASP5541
NCT07005154
P2RecruitingProstate Cancer; Metastatic Castration-Resistant Prostate Cancer2182032-05-31